Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2021
February 04, 2021 at 02:16 am EST
Share
Terumo Corporation provided consolidated earnings guidance for the fiscal year ending March 31, 2021. For the period, the company expected revenue of JPY 600,000 million, operating profit of JPY 97,500 million, profit for the year attributable to the owners of the parent of JPY 75,000 million and earnings per share of JPY 99.33.
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
TERUMO CORPORATION 
